HomeMarket News Pasithea Therapeutics Gains FDA Approval &...

Pasithea Therapeutics Gains FDA Approval & Conducts Stock Split Pasithea Therapeutics Gains FDA Approval & Conducts Stock Split

Actionable Trade Ideas

always free

FDA written on wooden cube with keyboard , calculator, chart,glasses.Business concept

Iryna Drozd

Pasithea Therapeutics (NASDAQ:KTTA) recently underwent a significant corporate maneuver, conducting a 1-for-20 reverse stock split. Simultaneously, the company broke the news that the FDA has given the green light for Phase 1 testing of its potential oncology blockbuster, PAS-004.

Coming to light in an SEC filing submitted on December 28, the reverse stock split is poised to unleash a fresh trading landscape for split-adjusted shares as of the market’s opening bell on Tuesday, January 2.

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.